During the last session, Kiora Pharmaceuticals Inc (NASDAQ:KPRX)’s traded shares were 0.12 million, with the beta value of the company hitting -0.68. At the end of the trading day, the stock’s price was $3.02, reflecting an intraday gain of 2.72% or $0.08. The 52-week high for the KPRX share is $4.86, that puts it down -60.93 from that peak though still a striking 16.89% gain since the share price plummeted to a 52-week low of $2.51. The company’s market capitalization is $9.19M, and the average intraday trading volume over the past 10 days was 0.13 million shares, and the average trade volume was 422.74K shares over the past three months.
Kiora Pharmaceuticals Inc (KPRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. KPRX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.58.
Kiora Pharmaceuticals Inc (NASDAQ:KPRX) trade information
Kiora Pharmaceuticals Inc (KPRX) registered a 2.72% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.72% in intraday trading to $3.02, hitting a weekly high. The stock’s 5-day price performance is -4.43%, and it has moved by -4.43% in 30 days. Based on these gigs, the overall price performance for the year is -43.66%. The short interest in Kiora Pharmaceuticals Inc (NASDAQ:KPRX) is 16835.0 shares and it means that shorts have 1.7 day(s) to cover.
Kiora Pharmaceuticals Inc (KPRX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -85.96% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 750k as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 750k by the end of current fiscal year.
While earnings are projected to return -346.55% in 2025.
KPRX Dividends
Kiora Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-May-09. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Kiora Pharmaceuticals Inc (NASDAQ:KPRX)’s Major holders
Kiora Pharmaceuticals Inc insiders own 3.60% of total outstanding shares while institutional holders control 45.65%, with the float percentage being 47.35%.
